Susquehanna International Group, LLP Otonomy, Inc. Put Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2021 Nov 15, 2021	SELL	$1.22 - $2.2 $41,968 - $75,680	-34,400 Reduced 72.27%	13,200 $25,000
Q2 2021 Aug 11, 2021	SELL	$2.06 - $2.67 $27,192 - $35,244	-13,200 Reduced 21.71%	47,600 $106,000
Q1 2021 May 17, 2021	SELL	$2.49 - $6.23 $24,900 - $62,300	-10,000 Reduced 14.12%	60,800 $155,000
Q4 2020 Feb 16, 2021	BUY	$3.48 - $6.47 $198,360 - $368,790	57,000 Added 413.04%	70,800 $458,000
Q1 2020 May 15, 2020	BUY	$1.58 - $4.06 $21,804 - $56,027	13,800 New	13,800 $27,000
Q4 2018 Feb 14, 2019	SELL	$1.51 - $2.93 $66,440 - $128,920	-44,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$2.6 - $3.95 $67,860 - $103,095	26,100 Added 145.81%	44,000 $121,000
Q1 2018 May 15, 2018	SELL	$4.05 - $6.1 $104,895 - $157,990	-25,900 Reduced 59.13%	17,900 $75,000
Q4 2017 Feb 14, 2018	BUY	$2.8 - $5.55 $6,440 - $12,765	2,300 Added 5.54%	43,800 $243,000
Q3 2017 Nov 14, 2017	BUY	$3.2 - $20.8 $132,800 - $863,200	41,500	41,500 $135,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.